Infant nutrition company Biotime is just the latest of such companies within China to modify its business practices following the announcement of an antirust investigation into the sector by Chinese authorities. The nation’s National Reform and Development Commission launched a probe into various makers of infant formula for suspicion of price-fixing. Biostime announced Tuesday plans to revise contracts with its distributors, according to reports. The case is particular, however, as reports say the price-fixing probe focuses on foreign companies in the market; Biostime is a domestic company. The company’s wholly-owned Chinese subsidiary is currently under investigation by the NDRC.
Featured News
Apple Opens Early Settlement Discussions With DOJ
Jul 17, 2026 by
CPI
South Korean Steelmaker POSCO Expands Supplier Support Pact With Antitrust Regulator
Jul 16, 2026 by
CPI
FCC’s Carr Criticizes California-Led Bid to Block Paramount-Warner Bros. Discovery Deal
Jul 16, 2026 by
CPI
EU Top Court Upholds Antitrust Powers to Seize Corporate Emails
Jul 16, 2026 by
CPI
Uber Launches $14.8 Billion Bid for Delivery Hero in Landmark Food Delivery Deal
Jul 16, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Agentic AI & Antitrust
Jul 16, 2026 by
CPI
AI Agents and Collusion: The Two Faces of Agentic AI
Jul 16, 2026 by
Giovanna Massarotto
Agentic AI’s Regulatory Conundrum
Jul 16, 2026 by
Anant Raut
Inter-AI-Agent Competition
Jul 16, 2026 by
Stefan Thomas
Navigating the Increasing Regulatory Scrutiny of AI-Pricing Tools: Competition and Other Emerging Risks
Jul 16, 2026 by
Mark Krotoski & Vinny Sidhu